利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.027 秒)

    Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
    1.
    发明公开
    Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia 审中-公开
    Verwendung von antagonistischen anti-CD40-Antikörpernzur Behandlung von chronischer lymphatischerLeukämie

    公开(公告)号：EP2243491A1

    公开(公告)日：2010-10-27

    申请号：EP10007491.3

    申请日：2004-11-04

    申请人： Novartis Vaccines and Diagnostics, Inc. ,  XOMA Technology Ltd.

    发明人： Long, Li ,  Luqman, Mohammad ,  Yabannavar, Asha ,  Zaror, Isabel ,  Aukerman, Sharon Lea

    IPC分类号： A61K39/395 ,  A61P35/02

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    摘要： Methods of therapy for treating a subject for an autoimmune disease and/or inflammatory disease are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits CD40L-mediated stimulation of CD40-expressing cells, and thus inhibits survival and signaling pathways of human CD40-expressing cells that are mediated by CD40L.

    摘要翻译： 提供了用于治疗受试者自身免疫性疾病和/或炎性疾病的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有明显的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗剂活性有利地抑制CD40L介导的表达CD40的细胞的刺激，从而抑制由CD40L介导的人CD40表达细胞的存活和信号传导途径。

    Methods of therapy for cancers expressing the CD40 antigen
    2.
    发明公开
    Methods of therapy for cancers expressing the CD40 antigen 审中-公开
    Verfahren zur Behandlung von Krebs mit Expression des CD40-Antigens

    公开(公告)号：EP2255828A1

    公开(公告)日：2010-12-01

    申请号：EP10006780.0

    申请日：2004-11-04

    申请人： Novartis Vaccines and Diagnostics, Inc. ,  XOMA Technology Ltd.

    发明人： Long, Li ,  Luqman, Mohammad ,  Yabannavar, Asha ,  Zaror, Isabel ,  Hurst, Deborah ,  Lopes de Menezes, Daniel E.

    IPC分类号： A61K39/395 ,  A61P35/02

    CPC分类号： C07K16/2878 ,  A61K38/2013 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Methods of treating a subject for a cancer comprising neoplastic cells expressing the CD40 cell surface antigen are provided. The methods comprise combination therapy with interleukin-2 (IL-2) or biologically active variant thereof and at least one antagonist anti-CD40 antibody or antigen-binding fragment thereof. In some embodiments, these two therapeutic agents are concurrently administered as two separate pharmaceutical compositions, one containing IL-2 or biologically active variant thereof, which is administered according to a constant IL-2 dosing regimen or a two-level IL-2 dosing regimen, the other containing the antagonist anti-CD40 antibody or suitable antigen binding fragment thereof, which is administered according to a weekly dosing regimen, or alternatively is dosed once every two, three, or four weeks.; Administering of these two agents together potentiates their effectiveness in promoting a positive therapeutic response. The methods find use in treating CD40-expressing cancers, including B-cell related cancers and solid tumors.

    摘要翻译： 提供了治疗受试者包括表达CD40细胞表面抗原的肿瘤细胞的方法。 所述方法包括与白细胞介素-2（IL-2）或其生物活性变体和至少一种拮抗性抗CD40抗体或其抗原结合片段的组合疗法。 在一些实施方案中，这两种治疗剂同时作为两种单独的药物组合物，一种含有IL-2或其生物活性变体的药物组合物，其根据恒定的IL-2给药方案或两级IL-2给药方案 ，另一种含有根据每周给药方案施用的拮抗性抗-CD40抗体或其合适的抗原结合片段，或者另外每两，三或四周一次给药。 一起对这两种药物的治疗可以增强其在促进积极的治疗反应方面的有效性。 该方法可用于治疗CD40表达的癌症，包括B细胞相关的癌症和实体瘤。

    Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
    4.
    发明公开
    Methods of therapy for solid tumors expressing the CD40 cell-surface antigen 审中-公开
    Verfahren zur Therapie von soliden Tumoren mit CD40-Zelloberflächenantigenexpression

    公开(公告)号：EP2301575A1

    公开(公告)日：2011-03-30

    申请号：EP10075331.8

    申请日：2004-11-04

    申请人： Novartis Vaccines and Diagnostics, Inc. ,  XOMA Technology Ltd.

    发明人： Long, Li ,  Luqman, Mohammad ,  Yabannavar, Asha ,  Zaror, Isabel

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    摘要： Methods of therapy are provided for treating a subject for a solid tumor that comprises carcinoma cells expressing the CD40 cell-surface antigen. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a subject in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Binding of the anti-CD40 antibody or suitable antigen-binding fragment thereof beneficially inhibits growth of solid tumors via ADCC-dependent killing of the CD40-expressing carcinoma cells.

    摘要翻译： 提供治疗方法用于治疗包括表达CD40细胞表面抗原的癌细胞的实体瘤的受试者。 所述方法包括向有需要的受试者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有明显的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其合适的抗原结合片段的结合有利地通过ADCC依赖性杀死表达CD40的癌细胞来抑制实体瘤的生长。

    Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
    5.
    发明公开
    Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma 审中-公开
    Verwendung von antagonistischen-anti-CD40-monoklonalenAntikörpernzur Behandlung von multiplem Myelom

    公开(公告)号：EP2243492A1

    公开(公告)日：2010-10-27

    申请号：EP10007492.1

    申请日：2004-11-04

    申请人： Novartis Vaccines and Diagnostics, Inc. ,  XOMA Technology Ltd.

    发明人： Long, Li ,  Luqman, Mohammad ,  Yabannavar, Asha ,  Zaror, Isabel

    IPC分类号： A61K39/395 ,  A61P35/02

    CPC分类号： C07K16/2878 ,  A61K38/2013 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  A61K2300/00

    摘要： Methods of therapy for treating a subject for multiple myeloma are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti- antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing multiple myeloma cells.

    摘要翻译： 提供了治疗多发性骨髓瘤受试者的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有明显的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗体或其抗原结合片段的拮抗剂活性有利地抑制人CD40表达多发性骨髓瘤细胞的增殖和/或分化。

    Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
    8.
    发明公开
    Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection 审中-公开
    用拮抗性抗CD40抗体的自身免疫性疾病和炎症性疾病和器官移植的治疗rejection-

    公开(公告)号：EP2248830A1

    公开(公告)日：2010-11-10

    申请号：EP10007970.6

    申请日：2004-11-04

    申请人： Novartis Vaccines and Diagnostics, Inc.

    发明人： Long, Li ,  Luqman, Mohammad ,  Yabannavar, Asha ,  Zaror, Isabel

    IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P37/06 ,  A61P29/00

    CPC分类号： C07K16/2878 ,  A61K38/2013 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Methods of therapy for treating a subject for an autoimmune disease and/or inflammatory disease are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits CD40L-mediated stimulation of CD40-expressing cells, and thus inhibits survival and signaling pathways of human CD40-expressing cells that are mediated by CD40L.

    摘要翻译： 提供了用于在自身免疫性疾病和/或炎性疾病治疗的受试者进行治疗的方法。 该方法包括施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段的其向需要其的患者。 拮抗性抗CD40抗体或其抗原结合片段是免费显著的激动活性，但展品拮抗剂活性。当抗体结合于人CD40表达细胞将CD40抗原。 所述抗CD40抗体或抗原结合片段的拮抗剂活性及其抑制有益CD40L-介导的CD40表达细胞的刺激，和因此抑制生存和人CD40表达细胞的信号传导途径并通过CD40L介导的。